Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/COA1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/COA1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/COA1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/COA1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/COA1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/COA1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00325706 | Prostate | BPH | response to progesterone | 16/3107 | 37/18723 | 1.22e-04 | 1.10e-03 | 16 |
GO:00084063 | Prostate | BPH | gonad development | 58/3107 | 221/18723 | 1.73e-04 | 1.48e-03 | 58 |
GO:000941016 | Prostate | BPH | response to xenobiotic stimulus | 106/3107 | 462/18723 | 2.24e-04 | 1.79e-03 | 106 |
GO:005087817 | Prostate | BPH | regulation of body fluid levels | 89/3107 | 379/18723 | 3.08e-04 | 2.37e-03 | 89 |
GO:00451373 | Prostate | BPH | development of primary sexual characteristics | 58/3107 | 227/18723 | 3.67e-04 | 2.71e-03 | 58 |
GO:00075483 | Prostate | BPH | sex differentiation | 68/3107 | 276/18723 | 3.75e-04 | 2.76e-03 | 68 |
GO:00607117 | Prostate | BPH | labyrinthine layer development | 17/3107 | 44/18723 | 3.88e-04 | 2.84e-03 | 17 |
GO:00323558 | Prostate | BPH | response to estradiol | 38/3107 | 141/18723 | 1.25e-03 | 7.57e-03 | 38 |
GO:00435433 | Prostate | BPH | protein acylation | 58/3107 | 243/18723 | 2.14e-03 | 1.19e-02 | 58 |
GO:00165733 | Prostate | BPH | histone acetylation | 39/3107 | 152/18723 | 2.86e-03 | 1.50e-02 | 39 |
GO:00183933 | Prostate | BPH | internal peptidyl-lysine acetylation | 40/3107 | 158/18723 | 3.30e-03 | 1.71e-02 | 40 |
GO:00064753 | Prostate | BPH | internal protein amino acid acetylation | 40/3107 | 160/18723 | 4.17e-03 | 2.06e-02 | 40 |
GO:0045664 | Prostate | BPH | regulation of neuron differentiation | 46/3107 | 196/18723 | 7.95e-03 | 3.47e-02 | 46 |
GO:00308799 | Prostate | BPH | mammary gland development | 34/3107 | 137/18723 | 8.77e-03 | 3.75e-02 | 34 |
GO:00448494 | Prostate | BPH | estrous cycle | 7/3107 | 16/18723 | 9.80e-03 | 4.13e-02 | 7 |
GO:00075848 | Prostate | BPH | response to nutrient | 41/3107 | 174/18723 | 1.09e-02 | 4.50e-02 | 41 |
GO:00309004 | Prostate | BPH | forebrain development | 80/3107 | 379/18723 | 1.19e-02 | 4.82e-02 | 80 |
GO:004854519 | Prostate | Tumor | response to steroid hormone | 118/3246 | 339/18723 | 4.46e-15 | 6.94e-13 | 118 |
GO:006145816 | Prostate | Tumor | reproductive system development | 133/3246 | 427/18723 | 1.24e-12 | 1.15e-10 | 133 |
GO:004860815 | Prostate | Tumor | reproductive structure development | 131/3246 | 424/18723 | 3.48e-12 | 2.89e-10 | 131 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
COA1 | SNV | Missense_Mutation | novel | c.355G>A | p.Glu119Lys | p.E119K | Q9GZY4 | protein_coding | deleterious(0) | possibly_damaging(0.751) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
COA1 | SNV | Missense_Mutation | | c.229G>A | p.Asp77Asn | p.D77N | Q9GZY4 | protein_coding | deleterious(0.03) | probably_damaging(0.91) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
COA1 | insertion | In_Frame_Ins | novel | c.340_341insAAGGAGTAGAGACGACCCAGAAGACCCAGCTTGCTTCTAGTCCAT | p.Arg114delinsLysGlyValGluThrThrGlnLysThrGlnLeuAlaSerSerProTrp | p.R114delinsKGVETTQKTQLASSPW | Q9GZY4 | protein_coding | | | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
COA1 | SNV | Missense_Mutation | novel | c.247G>A | p.Asp83Asn | p.D83N | Q9GZY4 | protein_coding | deleterious(0.04) | possibly_damaging(0.833) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
COA1 | SNV | Missense_Mutation | | c.146T>C | p.Leu49Ser | p.L49S | Q9GZY4 | protein_coding | tolerated(0.11) | benign(0.079) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
COA1 | SNV | Missense_Mutation | rs140065703 | c.82N>A | p.Gly28Arg | p.G28R | Q9GZY4 | protein_coding | deleterious(0) | probably_damaging(0.946) | TCGA-CK-5916-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
COA1 | insertion | Frame_Shift_Ins | novel | c.365_366insT | p.Leu122PhefsTer20 | p.L122Ffs*20 | Q9GZY4 | protein_coding | | | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
COA1 | SNV | Missense_Mutation | | c.229N>T | p.Asp77Tyr | p.D77Y | Q9GZY4 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
COA1 | SNV | Missense_Mutation | rs751652291 | c.32N>A | p.Arg11Gln | p.R11Q | Q9GZY4 | protein_coding | tolerated(0.67) | benign(0) | TCGA-D1-A16X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
COA1 | SNV | Missense_Mutation | | c.229G>A | p.Asp77Asn | p.D77N | Q9GZY4 | protein_coding | deleterious(0.03) | probably_damaging(0.91) | TCGA-D1-A2G5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |